CentralCharts: Supercharge your portfolio with groundbreaking tools.

Exclusive 30-count bottle to be available at over 2,900 stores across the United States SUNRISE, FL / ACCESSWIRE / June 1, 2024 / Fungies, a leading brand in the functional mushroom supplement industry, is thrilled to announce a significant expansion of its retail distribution. As part of its "Making Mushrooms Mainstream" mission , the innovative brand's popular line of functional mushroom gummies will now be available in over 2,900 Walmart stores across the United States. This milestone is...

Hyundai Motor America Reports May 2024 Sales PR Newswire FOUNTAIN VALLEY, Calif., June 1, 2024 Total sales up 12% in May; YTD total sales increase 2% Best May for IONIQ 5, IONIQ 6, Tucson HEV, Santa Fe HEV, Palisade and Santa Cruz Hyundai May retail sales up 9% YOY; Volume led by Palisade, IONIQ 5 and Santa Fe HEV May EV sales up 42% YOY FOUNTAIN VALLEY, Calif. , June 1, 2024 /PRNewswire/ -- Hyundai Motor America reported total May sales of 78,485 units, a 12% increase compared with May 2023 ....

...

- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy recommended dose for expansion selected and expansion arms open for enrollment - - Preliminary data on WTX-124 administered to patients in combination with pembrolizumab showed that the combination was...

A collection of India-centric documentaries covering its fast-growing economy, China relations, religious tensions, the rise of ......

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of N-able, Inc. (NYSE: NABL) and Encourages Shareholders to Contact the Firm for Additional Information PR Newswire PHILADELPHIA, June 1, 2024 PHILADELPHIA , June 1, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating N-able, Inc. (NYSE: NABL) on behalf of the company's shareholders. The investigation seeks to determine whether N-able and/or the company's officers and directors violated the securities laws or breached...

NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM ( NCT04382664 ), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website:...